Judge narrows GSK's Coreg patent suits; Orexo's Zubsolv nabs expanded FDA approval; Cipla unveils new inhaler;

@FiercePharma: Local funds behind Mevion Medical's $200M China JV aimed as country's first proton therapy system. More from FiercePharmaAsia | Follow @FiercePharma

@CarlyHFierce: Mallinckrodt amps up hospital business with $1.3B Therakos buy. ICYMI | Follow @CarlyHFierce

> A U.S. federal judge narrowed two patent lawsuits filed by GlaxoSmithKline ($GSK) against two generics makers over its heart failure drug Coreg. Report

> Orexo said its opioid dependence drug Zubsolv won expanded approval for use in induction of buprenorphine maintenance therapy. Report

> India's Cipla unveiled a new inhaler for lung drugs that uses breath-actuated technology to deliver doses. Release

Medical Device News

@FierceMedDev: VisionGate sets sights on FDA approval for noninvasive lung cancer Dx. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: HistoSonics raises $2M to develop its ultrasound-based ablation device. Article | Follow @VarunSaxena2

@EmilyWFierce: Cyndi Lauper says "no" to potato sacks in $NVS psoriasis campaign. More from FiercePharmaMarketing | Follow @EmilyWFierce

> Google joins forces with Dexcom for miniaturized glucose monitor. Story

> TherOx raises $16.8M in funding round for its device to save heart tissue after an attack. Article

Biotech News

@FierceBiotech: We're looking for 2015's Fiercest women in biotech. More | Follow @FierceBiotech

@JohnCFierce: This is what happens when a company like $GSK fails at truly innovative R&D--you champion low risk, low margin stuff. More from FiercePharma | Follow @JohnCFierce

@DamianFierce: Why is the undervaluing never "arguable" or "marginal" or "if you really think about it?" More | Follow @DamianFierce

> Clovis pairs up with Roche on a high-profile immuno-oncology project. News

> Novavax offers hype and hope with an RSV 'breakthrough.' Article

> Baxalta's not swayed by Shire's 'lowball' $30B, CEO says. Story

> Adynxx eyes an IPO, late-stage program after pain drug clears a PhII hurdle. Article

Pharma Manufacturing News

> Feds indict Canada Drugs for sales of fake and foreign Avastin. More

> Boehringer Ingelheim recalls more than 358,000 inhalers. Report

> Bing to warn consumers about to land on illegal pharmacy sites. Item

> Daiichi Sankyo puts $80M into Tokyo vaccine plant. Story

> Taiwan pharma inspector arrested for taking drugmaker bribes. Article

Pharma Asia News

> HK-based Ally Bridge joins with WI Harper on $10M Cold Genesys Series B. Article

> U.S.-listed China Cord Blood soars on offer from China department store firm. More

> A new normal in China for pharmaceutical industry as reforms accumulate? Editor's corner

> Australia drug exports drop 30% as industry lobby group cites high manufacturing costs. Story

> U.S.-listed China Cord Blood soars on offer from China department store firm. Item

Drug Delivery News

> Galena launches Zuplenz nausea suppressor with MonoSol's oral film tech. Report

> Mannkind looking to use its inhaler in new therapeutic areas, not just diabetes. Item

> Liposomal drug delivery enters the spotlight in new Russian-U.S. report. Article

> Aerie to use GrayBug's delivery tech for sustained release of its ophthalmic candidates. Story

> Sanofi launches fast-acting, high-concentration insulin med Toujeo in the U.K. Article

And Finally... Chronic drug shortages in Venezuela have prompted patients to turn to treatments for dogs instead. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.